| Dear Voornaam
Well shortly be asking most Cancer Research UK award holders, institute group leaders and students to submit their research outputs to us. The submission window will be open from 6 February until 16 March watch out for an email from us with more details.
Sharing your research outputs and outcomes helps us understand and talk about the work we fund, communicate with our supporters and ultimately guides our research and funding strategy.
Thank you in advance for your support. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
JOIN US AT ELRIG'S CRISPR IN DRUG DISCOVERY On 78 February, ELRIG will host its 5th CRISPR in Drug Discovery Conference at the Kings Centre in Oxford. David Walter, a Group Leader for the joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre or FGC, will give a Spotlight Talk on 7 February at 5pm to discuss research opportunities associated with the centre.
The FGC uses state-of-the-art functional genetic screens, cancer modelling and big data processing all aimed at accelerating the discovery of new cancer medicines.
Registration is free. And if you cannot make the talk, visit our exhibition booth to meet the team. |
|
|---|
|
|---|
|
|
NEW IN BMJ OPEN: ANALYSIS ON THE LINK BETWEEN ETHNICITY AND CANCER STAGE AT DIAGNOSIS Black women from Caribbean and African backgrounds are up to two times more likely to receive a late-stage diagnosis for some cancers than White British women in England.
Using data from NHS England, we reviewed around 697,000 diagnoses of 6 cancer types from 20122016 in people belonging to one of 5 ethnic groups in England.
There are many possible reasons behind increased odds of late diagnoses in some ethnic groups: poorer symptom awareness, delays in seeking help and having to present to the GP multiple times before being referred for tests being only some of them. |
|
|---|
|
|---|
|
|
 STARVING CANCER INTO SUBMISSION When Oliver Maddocks was a postdoc in Karen Vousdens lab, they found cancer cells lacking serine and glycine didn't grow overturning the metabolic dogma of the time.
Several years on, Oliver combines an academic role at the University of Glasgow with head of research at Faeth Therapeutics, a company he co-founded to bring precision diets to the clinic. Juggling academic research, two young kids and the pandemic while starting up a company, Oliver talks to us about the excitement of working in an emerging field and what's in the pipeline for his multidisciplinary team.
|
|
|---|
|  HEAR FROM LEADERS IN CANCER RESEARCH AND INNOVATION Join our cancer innovation event on 14 February taking place at the Francis Crick Institute. Event Chairperson, Parker Moss of Genomics England will moderate a panel discussion and explore how different startups are driving innovation in cancer research.
Also, three entrepreneurs: Anjui Wu (Cansor), Ella Mi (ChronosDx) and Pedro Correa de Sampaio (Neobe Therapeutics) will talk about the challenges of bringing their novel research to market and offer advice on the process of commercialisation.
Cancer Research Horizons, the Crick Science Entrepreneur Network and Science Entrepreneur Club are sponsoring the event.
|
|
|---|
|
|---|
|
|
DE-RISK AND REFINE YOUR SCIENTIFIC VENTURE Panacea Stars latest Spring/Summer 2023 Develop programme will help you test your scientific proposition, find your strategic focus, and ensure that your concept truly addresses the most important market aspects.
Over the last 6 years, Panacea Stars has helped to nurture and develop more than 250 companies from idea to viable product. The top ten performers are now collectively valued at over 300m.
Apply before 19 February for the chance to receive 100k funding, legal/IP and fundraising support and mentorship from industry experts including senior executives from Cancer Research UK, McKinsey and Company, AstraZeneca and IBM.
|
|
|---|
|
|---|
|
|
 CALL FOR EDITORIAL BOARD MEMBERS The British Journal of Cancer has launched a new, fully open access sister journal, BJC Reports. The journal will focus on rapid publication and global research, providing a home for research that might not reach the threshold of the BJC but is still worthy of publication.
It is looking to create a diverse and international editorial board and inviting early- to mid-career researchers to join.
|
|
|---|
|  BOOSTING ANTI-CANCER ANTIBODIES BY REDUCING THEIR AFFINITY A new study in Nature has shown that immunomodulatory antibodies with low affinity to bind to a target could improve cancer treatments.
Researchers at the University of Southampton studied three different receptors (CD40, 4-1BB and PD-1) to understand their affinity and function relationship.
They observed there was better receptor clustering and signalling into immune cells was improved when the binding was looser. CD40 even showed better killing of tumour cells.
This low affinity binding approach presents a new tool for translation to treatment.
|
|
|---|
|
|---|
|
|
| | | Oxford, UK 07 February 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 10 February 2023 |
|
|---|
|
|---|
| | | London, UK 3:00 PM 14 February 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
